Company intelligence

AbbVie

BiotechNorth Chicago, Illinois, USAFounded 2012Website ↗

AbbVie at a glance

Founded
2012[1]
Headquarters
North Chicago, Illinois, USA[2]
  1. [1] Founded: Wikipedia (retrieved September 27, 2026)
  2. [2] Headquarters: Wikipedia (retrieved September 27, 2026)

Is this your company? Get featured or correct your listing →

Recent changes

  1. Sep 28, 2026ADARx's IPO Haul Grows To $535M With AbbVie In Pulse story
  2. Sep 24, 2026ADARx Prices Upsized IPO At $446M With AbbVie Backing Pulse story
  3. Sep 21, 2026AbbVie-Backed ADARx Sets Terms For $350M Nasdaq IPO Pulse story
  4. Sep 21, 2026ADARx Sets Terms For $350M IPO, AbbVie Buys In Pulse story

Latest Pulse

  1. Yosemite Closes $350M Fund II For Reed Jobs's Cancer BetsReed Jobs's venture firm Yosemite closed its second fund at $350 million, up from a $200 million first close in January, to back startups and research aimed at making cancer non-lethal.→
  2. ADARx's IPO Haul Grows To $535M With AbbVie InAbbVie's concurrent $89 million private placement pushed ADARx's total fresh capital from its $446M priced IPO to $535.3 million, with the pharma giant taking a stake alongside the public listing.→
  3. ADARx Prices $446M IPO, Debuts As ADRXADARx Pharmaceuticals priced an upsized $446 million IPO at $17 a share and began trading on the Nasdaq as ADRX, joining the fall biotech IPO window alongside its existing AbbVie drug partnership.→
  4. This Fall's IPO Cohort, Scored Deal By DealSix live IPO storylines this week produced wildly different outcomes -- from a 19% Hong Kong pop to a pulled US deal -- and the spread says this fall's IPO window rewards individual fundamentals, not just good timing.→
  5. ADARx Prices Upsized IPO At $446M With AbbVie BackingADARx Pharmaceuticals priced an upsized IPO at $17 per share, raising $446.3 million, with AbbVie separately buying up to 4.9% of the company in a concurrent private placement ahead of Thursday's Nasdaq debut.→
  6. AbbVie-Backed ADARx Sets Terms For $350M Nasdaq IPOADARx Pharmaceuticals set terms for a $350 million IPO at $15 to $17 a share, seeking to fund Phase 2 trials of its lead siRNA therapy for rare renal disease, after posting an $87.7 million net loss on $6.1 million of collaboration revenue.→
  7. TRex Bio, Retension File S-1s For Nasdaq IPOsTRex Bio and Retension Pharmaceuticals both filed S-1 registration statements for Nasdaq IPOs on the same day, joining a fall biotech listing wave with Eli Lilly backing TRex's autoimmune-disease pipeline.→
  8. ADARx Sets Terms For $350M IPO, AbbVie Buys InADARx Pharmaceuticals set terms for a $350 million Nasdaq IPO at $15-$17 a share targeting a $1.74 billion valuation, with AbbVie agreeing to buy a roughly 4.9% stake in a concurrent private placement.→
  9. ADARx Files for Nasdaq Listing With Three Drugs in ClinicThe siRNA biotech filed its S-1 on September 4 to trade as ADRX, with a pipeline spanning complement disease, hereditary angioedema and stroke prevention, and JPMorgan and Morgan Stanley leading.→

Coverage Timeline

newest first
  1. Sep 28, 2026IPOADARx's IPO Haul Grows To $535M With AbbVie In$535.3M total→
  2. Sep 24, 2026IPOADARx Prices Upsized IPO At $446M With AbbVie Backing$446.3M IPO→
  3. Sep 21, 2026IPOADARx Sets Terms For $350M IPO, AbbVie Buys In$350M IPO→

All Coverage

IPO
ADARx's IPO Haul Grows To $535M With AbbVie In
IPO$535.3M total

ADARx's IPO Haul Grows To $535M With AbbVie In

AbbVie's concurrent $89 million private placement pushed ADARx's total fresh capital from its $446M priced IPO to $535.3 million, with the pharma giant taking a stake alongside the public listing.

FOLLOW-UP
IPO
ADARx Prices Upsized IPO At $446M With AbbVie Backing
IPO$446.3M IPO

ADARx Prices Upsized IPO At $446M With AbbVie Backing

ADARx Pharmaceuticals priced an upsized IPO at $17 per share, raising $446.3 million, with AbbVie separately buying up to 4.9% of the company in a concurrent private placement ahead of Thursday's Nasdaq debut.

FOLLOW-UP
IPO
ADARx Sets Terms For $350M IPO, AbbVie Buys In
IPO$350M IPO

ADARx Sets Terms For $350M IPO, AbbVie Buys In

ADARx Pharmaceuticals set terms for a $350 million Nasdaq IPO at $15-$17 a share targeting a $1.74 billion valuation, with AbbVie agreeing to buy a roughly 4.9% stake in a concurrent private placement.

FOLLOW-UP

Value Add Research

Related Companies

Same sector
Scribe TherapeuticsIambic TherapeuticsAttovia TherapeuticsApnimedEli LillyRetension Pharmaceuticals

AbbVie FAQ

When was AbbVie founded and where is it based?

AbbVie was founded in 2012 and is headquartered in North Chicago, Illinois, USA, according to Wikipedia.